Found 4 matching trials
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
PHASE1Primary Objectives:
1. To determine the maximum tolerated dose (MTD) or ma...
Location
UC San Diego Moores Cancer Center
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
PHASE2The purpose of this study is to test the good and bad effects of an experim...
Location
UC San Diego Moores Cancer Center
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
PHASE1The purpose of this study is to evaluate the safety and tolerability of SF1...
Location
Scottsdale Clinical Research Institute
SF1126 for Patients With Relapsed or Refractory Neuroblastoma
PHASE1SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active ...
Location
Children's Hospital Los Angeles